Search Results - "PATEL, Hitesh K"

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) by Zarrinkar, Patrick P., Gunawardane, Ruwanthi N., Cramer, Merryl D., Gardner, Michael F., Brigham, Daniel, Belli, Barbara, Karaman, Mazen W., Pratz, Keith W., Pallares, Gabriel, Chao, Qi, Sprankle, Kelly G., Patel, Hitesh K., Levis, Mark, Armstrong, Robert C., James, Joyce, Bhagwat, Shripad S.

“…Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as…”
Get full text

A quantitative analysis of kinase inhibitor selectivity by Zarrinkar, Patrick P, Karaman, Mazen W, Herrgard, Sanna, Treiber, Daniel K, Gallant, Paul, Atteridge, Corey E, Campbell, Brian T, Chan, Katrina W, Ciceri, Pietro, Davis, Mindy I, Edeen, Philip T, Faraoni, Raffaella, Floyd, Mark, Hunt, Jeremy P, Lockhart, Daniel J, Milanov, Zdravko V, Morrison, Michael J, Pallares, Gabriel, Patel, Hitesh K, Pritchard, Stephanie, Wodicka, Lisa M

“…Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets 1 , 2 . The biological consequences of multi-kinase activity…”
Get full text

Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor by Chao, Qi, Sprankle, Kelly G, Grotzfeld, Robert M, Lai, Andiliy G, Carter, Todd A, Velasco, Anne Marie, Gunawardane, Ruwanthi N, Cramer, Merryl D, Gardner, Michael F, James, Joyce, Zarrinkar, Patrick P, Patel, Hitesh K, Bhagwat, Shripad S

“…Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than…”
Get full text

A small molecule-kinase interaction map for clinical kinase inhibitors by Zarrinkar, Patrick P, Floyd, Mark, Lai, Andiliy G, Atteridge, Corey E, Carter, Todd A, Galvin, Margaret, Mehta, Shamal A, Lélias, Jean-Michel, Wodicka, Lisa M, Benedetti, Michael G, Azimioara, Mihai D, Treiber, Daniel K, Insko, Darren E, Insko, Michael A, Edeen, Philip T, Gerlach, Jay L, Fabian, Miles A, Grotzfeld, Robert M, Lockhart, David J, Patel, Hitesh K, Milanov, Zdravko V, Ciceri, Pietro, Biggs, William H, Herrgard, Sanna, Velasco, Anne Marie, Ford, Julia M

“…Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring…”
Get full text

Inhibition of Drug-Resistant Mutants of ABL, KIT, and EGF Receptor Kinases by Carter, Todd A., Wodicka, Lisa M., Shah, Neil P., Velasco, Anne Marie, Fabian, Miles A., Treiber, Daniel K., Milanov, Zdravko V., Atteridge, Corey E., Biggs, William H., Edeen, Philip T., Floyd, Mark, Ford, Julia M., Grotzfeld, Robert M., Herrgard, Sanna, Insko, Darren E., Mehta, Shamal A., Patel, Hitesh K., Pao, William, Sawyers, Charles L., Varmus, Harold, Zarrinkar, Patrick P., Lockhart, David J.

“…To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the emergence of drug resistance in…”
Get full text

Structure of the kinase domain of an imatinib-resistant abl mutant in complex with the aurora kinase inhibitor VX-680 by YOUNG, Matthew A, SHAH, Neil P, SAWYERS, Charles L, KURIYAN, John, CHAO, Luke H, SEELIGER, Markus, MILANOV, Zdravko V, BIGGS, William H, TREIBER, Daniel K, PATEL, Hitesh K, ZARRINKAR, Patrick P, LOCKHART, David J

“…We present a high-resolution (2.0 A) crystal structure of the catalytic domain of a mutant form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is…”
Get full text

Self micro-emulsifying drug delivery system of tacrolimus: Formulation, in vitro evaluation and stability studies by Patel, Pranav, Patel, Hitesh, Panchal, Shital, Mehta, Tejal

“…Background: Tacrolimus has poor solubility in water ranging from 4 to 12 μg/mL. The oral bio availabilities of tacrolimus is poor and exhibits high intra and…”
Get full text

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors by Patel, Hitesh K., Grotzfeld, Robert M., Lai, Andiliy G., Mehta, Shamal A., Milanov, Zdravko V., Chao, Qi, Sprankle, Kelly G., Carter, Todd A., Velasco, Anne Marie, Fabian, Miles A., James, Joyce, Treiber, Daniel K., Lockhart, David J., Zarrinkar, Patrick P., Bhagwat, Shripad S.

“…A series of diaryl ureas with an amide substitution at the 4-position was prepared and found to be potent and selective FLT3 inhibitors with good oral…”
Get full text

Development and characterization of liquid and solid self-microemulsifying drug delivery system of Tacrolimus by Patel, HiteshK, Patel, PranavV, Patel, MandevB, Mehta, DhavalS, Misan, ChetanK

“…Tacrolimus is an immunosuppressant agent for the prevention and treatment of graft rejection in solid organ transplantation patients. Tacrolimus is a poorly…”
Get full text

Unusual presentation of advanced Coats' disease by Patel, H K, Augsburger, J J, Eagle, Jr, R C

“…The authors report the case of a 19-month-old boy with advanced Coats' disease whose presenting manifestation was turbid, lipoproteinaceous fluid filling the…”
Get more information